Sawada Kenichi, Fujishima Naohito, Hirokawa Makoto
Department of Internal Medicine III, Division of Haematology, Akita University Graduate School of Medicine, Akita, Japan.
Br J Haematol. 2008 Aug;142(4):505-14. doi: 10.1111/j.1365-2141.2008.07216.x. Epub 2008 May 28.
Pure red cell aplasia (PRCA) is a syndrome characterized by a severe normocytic anaemia, reticulocytopenia, and absence of erythroblasts from an otherwise normal bone marrow. Primary PRCA, or secondary PRCA which has not responded to treatment of the underlying disease, is treated as an immunologically-mediated disease. Although vigorous immunosuppressive treatments induce and maintain remissions in a majority of patients, they carry an increased risk of serious complications. Corticosteroids were used in the treatment of PRCA and this has been considered the treatment of first choice although relapse is not uncommon. Cyclosporine A (CsA) has become established as one of the leading drugs for treatment of PRCA. However, common concerns have been the number of patients treated with CsA who achieve sustained remissions and the number that relapse. This article reviews the current status of CsA therapy and compares it to other treatments for diverse PRCAs.
纯红细胞再生障碍性贫血(PRCA)是一种以严重正细胞性贫血、网织红细胞减少以及正常骨髓中无成红细胞为特征的综合征。原发性PRCA或对基础疾病治疗无反应的继发性PRCA被视为免疫介导性疾病。尽管积极的免疫抑制治疗可使大多数患者诱导缓解并维持缓解状态,但它们会增加严重并发症的风险。皮质类固醇曾用于PRCA的治疗,这一直被视为首选治疗方法,尽管复发并不罕见。环孢素A(CsA)已成为治疗PRCA的主要药物之一。然而,人们普遍关注的是接受CsA治疗并实现持续缓解的患者数量以及复发的患者数量。本文综述了CsA治疗的现状,并将其与其他治疗不同类型PRCA的方法进行比较。